Breast cancer is the most common cancer diagnosed in South African women, and one of the most intensively funded conditions in private healthcare — yet also one of the most misunderstood from a medical aid perspective. The gap between what medical aids must pay and what treatment actually costs can reach hundreds of thousands of rands.
What Is Breast Cancer?
Breast cancer arises when cells in the breast tissue multiply uncontrollably, forming a tumour. It is classified by hormone receptor status (oestrogen-positive, progesterone-positive, or negative), HER2 protein expression, and stage (I–IV). These classifications determine treatment protocol and, critically, which medicines and procedures a medical aid is required to fund.
The four main biological subtypes are: - Luminal A (ER+/PR+, HER2−, low Ki-67): Slow-growing; responds well to hormone therapy. - Luminal B (ER+/PR+, HER2+ or high Ki-67): More aggressive; may require chemotherapy. - HER2-enriched (HER2+): Requires HER2-targeted therapy (trastuzumab). - Triple-negative (ER−/PR−, HER2−): No targeted therapy available; treated with chemotherapy; highest urgency for clinical trial access.
South African Statistics
The National Cancer Registry (NCR) data consistently places breast cancer as the leading cancer in South African women. Estimated lifetime risk in SA is approximately 1 in 25 to 1 in 29 for women. In the private sector, breast cancer is among the top three conditions driving oncology sub-limit discussions.
Prescribed Minimum Benefits (PMB)
Breast cancer is covered under the Prescribed Minimum Benefits framework as a Level 1 oncological condition under the DOSA (Defined Benefit Option Structure Annexure) schedule. This means:
- Medical aids must fund treatment — they cannot simply deny breast cancer claims.
- PMB covers the minimum treatment standard — defined as diagnosis, staging, surgery, radiation, and chemotherapy using a designated service provider (DSP) formulary.
- HER2-targeted therapy (trastuzumab) is generally regarded as the PMB minimum treatment standard for HER2+ disease.
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are typically NOT classified as PMB minimum treatment; they require exceptional-needs authorisation from your scheme.
This distinction is critical. A patient with HER2+ breast cancer has a stronger PMB entitlement for trastuzumab than a patient with luminal A disease requiring a CDK4/6 inhibitor.
Treatment Pathway
Stage I–II (early-stage): Lumpectomy or mastectomy → sentinel node biopsy → radiation therapy → hormone therapy (tamoxifen or aromatase inhibitor for 5–10 years) ± chemotherapy for high-risk features.
Stage III (locally advanced): Neoadjuvant chemotherapy (before surgery) → surgery → radiation → targeted therapy if HER2+ → hormone therapy if receptor-positive.
Stage IV (metastatic): Treatment is palliative (to prolong life and manage symptoms). Options include chemotherapy cycles, CDK4/6 inhibitors (for ER+/HER2− disease), trastuzumab ± pertuzumab (for HER2+), immunotherapy (for triple-negative), and bone-targeted therapy for skeletal metastases.
Medication Costs in South Africa
Costs below are estimated. SAHPRA Single Exit Price (SEP) verification pending.
| Medication | Class | Estimated Monthly Cost |
|---|---|---|
| Trastuzumab (Herceptin) | HER2-targeted mAb | R25,000–R30,000 |
| Palbociclib (Ibrance) | CDK4/6 inhibitor | R40,000–R50,000 |
| Paclitaxel | Taxane chemotherapy | R6,000–R10,000 |
| Tamoxifen | SERM hormone therapy | R300–R400 |
| Letrozole | Aromatase inhibitor | R500–R700 |
The contrast between tamoxifen (~R350/month) and palbociclib (~R45,000/month) illustrates the enormous variation in treatment costs across breast cancer subtypes.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Early-stage (Stage I–II), surgery + radiation + tamoxifen | R50,000 – R150,000 |
| HER2+ with trastuzumab + chemotherapy | R150,000 – R450,000 |
| Metastatic ER+, CDK4/6 inhibitor (palbociclib) | R450,000 – R600,000+ |
| Metastatic triple-negative or HER2+ with combination biologics | R500,000 – R800,000+ |
These figures include specialist fees, diagnostics, and hospital admissions. They do not yet account for shortfalls above medical aid tariff.
The Oncology Sub-Limit: The Most Important Number on Your Plan
Every medical aid plan that funds oncology treatment does so up to a specified annual rand limit — the oncology sub-limit. This is separate from your overall annual threshold (your "above-threshold benefit") and is the single most important figure when comparing plans if you have a cancer diagnosis.
Common oncology sub-limits in the SA market range from R250,000 to R600,000 per year, with some comprehensive plans offering unlimited oncology (at commensurately higher premiums).
If your treatment costs exceed your oncology sub-limit, you pay the difference out of pocket. On a palbociclib protocol costing R540,000/year in medication alone, a R300,000 sub-limit leaves a R240,000 shortfall — before any specialist consultation shortfalls are added.
Gap Cover and the Overall Payment Limit
Gap cover is separate insurance that pays specialist shortfalls — the difference between what a specialist charges and what a medical aid tariff pays. The gap cover Overall Payment Limit (OPL) is approximately R220,000 per year across most SA gap cover policies.
In breast cancer, the following generate shortfalls: - Oncologist/medical oncologist consultation and infusion fees — specialists frequently bill at 200–500% of medical aid tariff. - Surgical specialist (general surgeon, plastic surgeon for reconstruction) — shortfalls on mastectomy and reconstruction can reach R30,000–R80,000 per procedure. - Anaesthesiologist — shortfall at every surgical procedure. - Pathologist and radiologist — shortfalls on biopsy, PET/CT, and MRI interpretation.
On a complex HER2+ treatment protocol, total specialist shortfalls can exceed the gap OPL (R220,000/year) well before the end of the treatment year. This is the critical risk that gap cover is designed to offset — but which it may not fully absorb in high-cost oncology cases.
What Medical Aids Must Cover (PMB vs. What They Often Fund in Practice)
| Item | PMB Obligated? | Notes |
|---|---|---|
| Diagnosis (biopsy, imaging) | Yes | PMB covers diagnosis |
| Surgery (lumpectomy, mastectomy) | Yes | At DSP rates |
| Radiation therapy | Yes | PMB minimum standard |
| Standard chemotherapy | Yes | PMB minimum standard |
| Trastuzumab (HER2+) | Generally yes | Confirm with your scheme |
| Palbociclib / CDK4/6 inhibitors | Usually no — exceptional needs | Most schemes require motivation |
| Pertuzumab (Perjeta) | Usually no — exceptional needs | — |
| Pembrolizumab (triple-negative) | Unlikely PMB — exceptional needs | — |
| Breast reconstruction | Varies | Some plans include; others exclude |
Biomarker Testing
Your treatment plan depends on biomarker results. Tests routinely required: - ER/PR/HER2 immunohistochemistry — standard pathology; usually funded. - Ki-67 proliferation index — standard; usually funded. - Oncotype DX / MammaPrint (genomic assays) — can cost R15,000–R30,000; NOT always PMB-funded; important for decisions on whether to add chemotherapy to hormone therapy.
Talk to Eldon
See which plans pay for breast cancer treatment →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).